IN8bio

📍 New York, United States🗓 Founded 2016👥 30 employees💰 Last funded Jun 2021
Biotechnology Research🌐 in8bio.com
Website LinkedIn
IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in IN8bio?
IN8bio has 1 investors on record on gritt.io, 1 mid-stage.
When did IN8bio last raise funding?
The most recent investment in IN8bio recorded on gritt.io was in June 2021.
When was IN8bio founded?
IN8bio was founded in 2016.
What industry is IN8bio in?
IN8bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is IN8bio based?
IN8bio is headquartered in New York, United States.